Immunai

Immunai is a biotechnology and computational immunology company founded in 2018, co-founded by Luis Voloch and Noam Solomon. The company is headquartered in New York, with a significant R&D presence in Tel Aviv. It is privately held.

Immunai builds a large-scale proprietary immunological database combined with machine learning models to map the human immune system at single-cell resolution. The core thesis is that a detailed, structured map of immune cell states and transitions enables better design and optimization of immunotherapies, particularly cell therapies and cancer treatments.

Immunai's primary product is a platform that integrates single-cell multi-omic data — capturing gene expression, protein levels, and other molecular signals simultaneously from individual immune cells — with machine learning to generate predictive models of immune response. The intended buyers are biopharmaceutical companies developing cell therapies, CAR-T programs, and other immuno-oncology treatments, with the platform aimed at R&D and translational science teams within those organizations. The scientific moat is the proprietary immunological atlas built from accumulated single-cell datasets, which grows in predictive value as more data is ingested.